Recognizing the Broader Value of Meningococcal Vaccination: A Matter of Evidence, Ability, or Willingness?

•The argument around the broader value generation of meningococcal vaccination is supported by high quality evidence across multiple areas beyond healthcare sector effects, including health-related externalities (caregiver’s health gains), allocative value (severity of disease), and societal economic effects (patient’s lifetime productivity gains).•Evidence gaps are still a potential barrier in demonstrating the relevance of broader value elements such as risk reduction gains, outbreak prevention due to changes and emergence of previously underrepresented serogroup variants, public sector costs, macroeconomic effects, and indirect patient’s cost.•Using case studies of meningococcal B vaccination value assessments, we found that value recognition has been mixed due to the limited scope of the health technology assessment perspective or guidelines and the use of evaluation methods that do not fully capture broader value. To ensure that the most efficient resource allocation outcomes are achieved, countries should consider a case for improving their perspective and methodological ability to assess broader value elements accurately.